New CAR T Cell Therapy May Target Lung Fibrosis
A new preclinical study shows promise for reducing lung scarring using engineered cells in a mouse model.
Updated on Oct. 24, 2026 in Asthma
Live Poll
Do you believe new CAR T-cell therapy research offers a promising future for treating lung disease?
Researchers have developed experimental CAR T cells designed to target fibroblast activation protein-alpha, a potential new approach for treating pulmonary fibrosis. The preclinical study demonstrated that these cells could reduce scarring and improve lung function in mice.
Why it matters
Current medical therapies for pulmonary fibrosis are limited in their ability to eliminate the pathogenic cells that cause lung scarring. This development offers a potential new strategy to target these specific cells, though findings remain restricted to laboratory models.
This preclinical study utilized single-cell RNA sequencing to confirm target expression before testing CAR T cells in a bleomycin-induced mouse model of lung fibrosis. While researchers observed a reduced fibrotic burden and enhanced respiratory metrics, the work remains strictly preliminary.
The details
The treatment works by engineering T cells to recognize and bind to fibroblast activation protein-alpha, which is highly expressed in myofibroblasts within fibrotic lung tissue. By targeting these pathogenic fibroblasts, the CAR T cells act to selectively reduce the cells responsible for excessive collagen deposition and tissue scarring. This mechanism represents a shift toward using precision immunotherapy to address the structural changes characteristic of pulmonary fibrosis.
Timeline
October 24, 2026: The research findings were published.
Health Landscape
This study adapts the established success of CAR T-cell therapy in oncology to address the pathogenic fibroblasts involved in lung fibrosis. It marks an experimental shift in applying precision immunotherapy to manage non-malignant, chronic structural diseases of the lung.
Because this research was conducted in a laboratory setting using mice, there are no immediate changes to existing patient care or treatment options. Those living with pulmonary fibrosis should continue to consult with their pulmonologist regarding standard management and any relevant clinical trials.
The takeaway
This study highlights a new experimental direction for targeting the cellular drivers of lung scarring. Patients and caregivers should remain informed about ongoing research developments through conversations with their medical care team.
Further reading
For more on the latest research in lung conditions, visit our Asthma section.
More information
Read the full peer-reviewed research article for technical details on the study design.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new CAR T-cell therapy research offers a promising future for treating lung disease?
